SAN DIEGO, March 09, 2017 (GLOBE NEWSWIRE) -- TearLab Corporation (NASDAQ:TEAR) (TSX:TLB) ("TearLab" or the "Company") today reported its consolidated financial results for the fourth quarter and twelve months ended December 31, 2016. All dollar amounts are expressed in U.S. currency and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise.

Recent Highlights
  • Achieved full-year 2016 revenue of $28.0 million, an increase of 11% over $25.2 million in 2015
  • Reduced loss from operations by 49% compared to 2015, from $31.5 million to $16.0 million
  • Received CE Mark approval for next generation platform, providing regulatory clearance in the European Union and European Free Trade Association member countries
  • Received regulatory approval from the Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) in Mexico
  • Received regulatory approval in the Republic of Korea by the Ministry of Health and Welfare
  • Submitted regulatory filing for approval in the Federative Republic of Brazil
  • Launched the TearLab Osmolarity System in the Republic of India through partner My HealthSkape PVT Ltd.
  • Announced today that the Company is beginning a process to explore strategic alternatives

For the three months ended December 31, 2016, TearLab's net revenues were $7.1 million, up 5% from $6.8 million for the same period in 2015. A net total of 183 TearLab Osmolarity® Systems were added in the fourth quarter of 2016, of which 64 were under the Company's new Flex program and 26 were purchased outside of the United States.

The following table sets out the estimated annualized revenue per U.S. device and account analysis for the fourth quarter ended December 31, 2016:
                Annualized   Annualized
        Active   Active   Revenue   Revenue
Program                                                       Devices   Accounts   Per Device   Per Account
Purchased                                       645   573   $   2,469   $   2,779
Use          173   172   $   2,618   $   2,633
Masters                                                                             1,717   218   $   3,336   $   26,275
Flex         1,890   778   $   8,672   $   21,066
Total         4,425     1,741        
                     

The Company's reported net loss for the 2016 fourth quarter was approximately $4.3 million, or ($0.81) basic loss per share ($0.08 basic loss per share excluding the effect of the recent 1:10 reverse stock split), compared to a reported net loss of approximately $8.9 million, or ($2.64) basic loss per share ($0.26 basic loss per share excluding the effect of the recent 1:10 reverse stock split), in the fourth quarter of 2015. In addition, the Company's cash burn in the fourth quarter was $2.1 million, resulting in an ending cash balance of $15.5 million as of December 31, 2016.

"2016 was a year of transition for TearLab. We grew revenue through effective execution under our new, refocused commercial model, significantly improved our expense management and cash consumption, completed a successful $17.3 million financing and have advanced our next generation platform through its initial CE marking in Europe," said Seph Jensen, TearLab's Chief Executive Officer. "We continue to believe strongly in the potential of our technology, and we remain focused on advancing and expanding the use of in-vitro diagnostics in eye care with our current and next generation platforms. Nevertheless, our Board of Directors believe it is important that we explore all avenues to advance our mission of pioneering in-vitro diagnostics in eye care.  As a result, we have begun a process to explore strategic alternatives for TearLab. We have only just begun this process, and we continue working to execute under our new sales model and identify initiatives aimed at accelerating revenue growth while carefully managing expenses. However, we have a responsibility to explore any and all possible avenues to maximize shareholder value and are committed to doing so."

The Company also announced that it will move to quickly seek CE marking for the second inflammation biomarker that will, combined with osmolarity, comprise the first commercial test card on the new platform.  The Company then plans to build a robust clinical data package and secure valuable feedback from global key opinion leaders in support of a 510(k) submission to the U.S. Food and Drug Administration, which is expected in the third quarter of 2017.

About TearLab Corporation

TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System.  TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  Forward-looking statements include, among others, statements concerning whether we will receive reimbursement approval in Korea, whether we will receive approval of the TearLab Osmolarity System in Brazil as well as the timing of receiving such approval, the market for dry eye patients in Korea, Brazil and India, the potential success in commercializing the TearLab Osmolarity System in these markets, the future relationships with our commercial partners and the potential interest in the TearLab Osmolarity System in these three markets by eye care professionals and patients, the extent and form of any selected strategic alternatives,  the timing and success of the CE Marking with an additional inflammatory marker, the timing of our potential 510(k) submission to the U.S. Food and Drug Administration and whether such submission will receive approval.  These forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are based on management's current, preliminary expectations and are subject to various risks and uncertainties. Many factors, risks and uncertainties may cause our actual results to differ materially from forward-looking statements, including the factors, risks, and uncertainties detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2016, expected to be filed with the SEC on March 10, 2017. We do not undertake to update any forward-looking statements except as required by law.
                     
TearLab Corp.            
Condensed Consolidated Statements of Operations            
(Expressed in U.S. Dollars (000's) except for number of shares and net loss per share)            
(Unaudited)            
    Three months            
     ended December 31,            
      2016       2015              
Revenue                    
  Product sales   $     6,416     $   5,790              
  Reader equipment rentals       705         1,001              
Total revenue     7,121       6,791              
Cost of goods sold                    
Cost of goods sold  (excluding amortization of intangible assets)     2,619       2,752              
Cost of goods sold - reader equipment depreciation     495       516              
Gross profit     4,007       3,523              
Operating expenses                    
Sales and marketing     3,287       4,416              
Clinical, regulatory and research & development        2,347         2,040              
General and administrative        1,566         3,531              
Amortization of intangible assets       100         356              
Impairment of long-lived assets     -         1,372              
Total operating expenses       7,300         11,715              
Loss from operations         (3,293 )       (8,192 )            
Other income (expense)       (1,047 )       (733 )            
Net loss and comprehensive loss   $     (4,340 )   $   (8,925 )            
Weighted average shares outstanding   - basic*       5,360,199         3,376,090              
Net loss per share   - basic*   $     (0.81 )   $   (2.64 )            
Weighted average shares outstanding   - diluted*       5,360,199         3,376,090              
Net loss per share   - diluted*   $     (0.81 )   $   (2.64 )            
                     
*  Restated for a 1-for-10 reverse stock split effected February 27, 2017.              

           
TearLab Corp.  
Condensed Consolidated Statements of Operations  
(Expressed in U.S. Dollars (000's) except for number of shares and net loss per share)  
    Year ended  
    December 31,  
    2016 (a)     2015    
Revenue          
  Product sales   $     23,809     $   20,325    
  Reader equipment rentals       4,205         4,831    
Total revenue     28,014       25,156    
Cost of goods sold          
Cost of goods sold  (excluding amortization of intangible assets)     10,188       10,825    
Cost of goods sold - reader equipment depreciation     2,130       1,732    
Gross profit     15,696       12,599    
Operating expenses          
Sales and marketing     14,397       19,349    
Clinical, regulatory and research & development        5,152         6,951    
General and administrative        11,057         14,935    
Amortization of intangible assets       1,066         1,501    
Impairment of long-lived assets       -           1,372    
Total operating expenses       31,672         44,108    
Loss from operations         (15,976 )       (31,509 )  
Other income (expense)       (3,944 )       (1,720 )  
Net loss and comprehensive loss   $     (19,920 )   $   (33,229 )  
Weighted average shares outstanding   - basic*       4,647,983         3,369,808    
Net loss per share   - basic*   $     (4.29 )   $   (9.86 )  
Weighted average shares outstanding   - diluted*       4,647,983         3,373,180    
Net loss per share   - diluted*   $     (4.29 )   $   (9.92 )  
           
*  Restated for a 1-for-10 reverse stock split effected February 27, 2017.          
(a)  Information as of, and for the year ended December 31, 2016 will be included in the Company's form 10-Kwhich we anticipate filing on, or about March 10, 2017.  
 

 
  TearLab Corp.
  Consolidated Balance Sheets
  (Expressed in U.S. Dollars (000's)
               
      December 31,   December 31,
      2016 (a)   2015  
  ASSETS            
  Current assets            
  Cash     $     15,471       $   13,838  
  Accounts receivable, net         2,279           3,021  
  Inventory         3,193           3,972  
  Prepaid expenses and other current assets         1,226         790  
  Total current assets       22,169         21,621  
               
  Fixed assets, net       4,178         5,352  
  Intangible assets, net       60         1,197  
  Other non-current assets       220         181  
  Total assets     $     26,627       $   28,351  
               
  LIABILITIES AND STOCKHOLDERS' EQUITY            
  Current liabilities            
  Accounts payable     $     1,858       $   2,292  
  Accrued liabilities       3,958         5,047  
  Deferred Rent       83         114  
  Obligations under warrants               29  
  Total current liabilities       5,899         7,482  
               
  Long-term debt         26,449         24,859  
               
  Total liabilities       32,348         32,341  
               
  Exchange right               250  
               
  Stockholders' equity (deficit)            
  Capital stock            
  Preferred Stock, $0.001 par value, 10,000,000 authorized, 2,764 and 0issued and outstanding at December 31, 2016 and December 31,2015, respectively                
                       
  Common stock, $0.001 par value, 9,500,000* and 6,500,000*authorized, 5,360,198*  and 3,376,090* issued and outstanding atDecember 31, 2016 and December 31, 2015, respectively       54         34  
  Additional paid-in capital       506,933         488,514  
  Accumulated deficit         (512,708 )         (492,788 )
  Total stockholders' equity (deficit)         (5,721 )         (4,240 )
  Total liabilities and stockholders' equity     $     26,627       $   28,351  
               
               
  *  Restated for a 1-for-10 reverse stock split effected February 27, 2017.      
  (a)  Information as of, and for the year ended December 31, 2016 will be included in the Company's form 10-Kwhich we anticipate filing on, or about March 10, 2017.
 

 
Investor Contact:The Ruth GroupLee RothTel: 646-536-7012lroth@theruthgroup.com